A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
NCT ID: NCT01464190
Last Updated: 2014-04-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
659 participants
INTERVENTIONAL
2011-09-30
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
NCT01324128
Study of Phosphate Levels in Patients With Chronic Kidney Disease
NCT00824460
PA21 Safety and Efficacy in Adult Chinese Subjects
NCT03644264
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
NCT01850602
Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
NCT00806481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PA21
PA21 (2.5 g tablet containing 500 mg iron)
Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Sevelamer carbonate
Sevelamer carbonate
Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PA21 (2.5 g tablet containing 500 mg iron)
Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Sevelamer carbonate
Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written Informed Consent
Exclusion Criteria
* Other significant medical conditions
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fresenius Medical Care North America
INDUSTRY
Vifor Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juergen Floege, MD
Role: PRINCIPAL_INVESTIGATOR
Medizinische Klinik II
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Antonio, Texas, United States
Medizinische Abteilung Nephrologie und Dialyse
Sankt Pölten, , Austria
CHU Sart Tilman
Liège, , Belgium
Clinical Hospital Center Rijeka
Rijeka, , Croatia
Hospital with Polyclinic Novy Jicin
Nový Jičín, , Czechia
KfH Nierenzentrum Berlin-Neukoelln
Berlin, , Germany
Vidzemes Hospital
Valmiera, , Latvia
JSC "Diaverum Clinics"
Klaipėda, , Lithuania
Teaching Hospital no.1 of Medical University of Lodz
Lodz, , Poland
Dialmed Clinic SRL
Sibiu, , Romania
Kemerovo Regional hospital
Kemerovo, , Russia
Zvezdara Clinical Medical Center
Belgrade, , Serbia
St Augustines Hospital
Durban, , South Africa
Mykolayiv Regional Hospital
Mykolayiv, , Ukraine
Dorset County Hospital NHS Foundation Trust
Dorset, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 Oct;22(4):480-491. doi: 10.1111/hdi.12663. Epub 2018 Apr 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA-CL-05B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.